Equity Research

Our research analysts hold advanced scientific or medical degrees and produce research that is widely read by the most prominent life science institutional investors

A Differentiated Model

Our equity research is expert-driven, high quality, and highly informed so that we can raise the visibility of covered companies and educate investors on compelling opportunities

We generate thoroughly researched and insightful "deep dive" analyses that provide value to investors

Expert engagement is at the core of our process and enables us to have informed views on complex topics

Our research is available on an open platform that is broadly distributed to top institutional investors, high net worth, family offices, and biopharma leadership

Research Snapshot

Our team is highly selective in choosing companies to cover, focusing on innovative science, disruptive clinical data, and capable management teams

Research staff
75% with MA/PhD/MD
Companies
under coverage
Person
distribution list
KOL events
in 2021 & 2022

Our Areas of Focus

  • Therapeutics
  • Medical Technology

Immunology and Inflammation

Celldex, Ventyx, Abivax, Immunovant, Viridian, Allakos, Eledon, InflaRx, Catalyst Biosciences, VYNE, Third Harmonic Bio

Oncology

Cogent, ALX Oncology, Vincerx, MEI Pharma, Pyxis Oncology, Olema

Rare Disease

Inhibrx, CymaBay, Aeglea, VectivBio, Larimar

Genetic Medicines

Rocket Pharmaceuticals, Verve Therapeutics, Tenaya Therapeutics, Renovacor

Ophthalmology

Oyster Point, Tarsus

Respiratory

Bellus Health

Nephrology

Calliditas Therapeutics, Vera Therapeutics

CNS

Avadel Pharmaceuticals

Medical Technology

Nano-X Imaging, Orchestra BioMed, BetaBionics

Digital Health

Dario Health, Better Therapeutics, Pear Therapeutics, Akili Interactive

Diagnostics

Lucira Health

Cardiovascular

CinCor Pharma

Key Research Activities

We utilize multiple tools for raising the visibility of our coverage universe and engaging with investors

Frequent, In-Depth Research

Deep-dive initiation reports, thought pieces, expert events, and sector analyses. On average, we issue a note every 1.5 months on all of our covered companies

Investor Events with KOLs

Calls, dinners, and other events to gather competitive intelligence from experts

Physician Surveys

Interviewing or surveying practicing physicians to understand preferences, unmet needs, and reactions to target product profiles

Medical Meeting Coverage

Presence at and coverage of major medical meetings across key therapeutic areas

Sector Analyses

Thematic pieces dedicated to emerging therapeutic areas of investor interest

Scientific Literature Analysis

Appreciation of cutting-edge developments in our therapeutic areas

We are a full service investment bank specializing in the life sciences and healthcare